Key Developments: Nxstage Medical Inc (NXTM.O)
13.41USD
12:21pm EDT
$0.02 (+0.15%)
$13.07
$13.43
$13.51
$13.26
87,644
303,657
$17.15
$10.15
Latest Key Developments (Source: Significant Developments)
NxStage Medical Inc Issues Q2 2013 Guidance; Net Profit Below Analysts' Estimates; Reaffirms FY 2013 Guidance
NxStage Medical Inc announced that for the second quarter of 2013, it expects revenue to be in a range of $64.0-$65.5 million, net loss in the range of $4.0-$5.0 million or $(0.07)-$(0.08) per share. For fiscal 2013, it reaffirming both guidance. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $64.5 million, net profit of $(3.9) million, and EPS of $(0.07) for the second quarter of 2013; net profit of $(14) million, and EPS of $(0.24) for fiscal 2013. Full Article
NxStage Medical Inc Announces Resignation Of Philippe O. Chambon-Form 8-K
NxStage Medical Inc reported in its Form 8-K that on April 23, 2013, Philippe O. Chambon notified NxStage Medical, Inc. (Company) that he was resigning from the Company’s Board of Directors effective immediately. Full Article
NxStage Medical Inc Issues Q1 2013 Guidance Below Analysts' Estimates; Issues FY 2013 Guidance; Earnings Guidance Below Analysts' Estimates
NxStage Medical Inc announced that for the first quarter of 2013, it expects revenue to be in a range of $60.5-$62.0 million, which includes an expected one-time reduction to revenue of approximately $0.5-$1.0 million related to its plan to transition to a direct sales operation from a distribution relationship in the UK. The Company expects a net loss in the range of $4.5 to $5.5 million or $(0.08) to $(0.09) per share. For fiscal 2013, the Company is forecasting revenue to be between $265 and $270 million, and a net loss in the range of $13 to $17 million or $(0.22) to $(0.28) per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $64.0 million, net profit of $(2.7) million, and EPS of $(0.05) for the first quarter of 2013; revenues of $268 million, net profit of $(7.7) million, and EPS of $(0.12) for fiscal 2013. Full Article
NxStage Medical Inc Announces CE Mark Approval For Nocturnal Home Hemodialysis
NxStage Medical Inc announced CE Mark approval for nocturnal home hemodialysis with the NxStage System One. NxStage expects to begin marketing the System One for nocturnal dialysis in countries that recognize the CE Mark approval process in the second half of 2013. Full Article
NxStage Medical Inc Lowers High End Of Prior FY 2012 Revenue Guidance; Broadens FY 2012 Earnings Guidance; Raises High End Of Prior FY 2012 EBITDA Guidance; Issues Q4 2012 Mixed Guidance
NxStage Medical Inc announced that for fiscal 2012, it expects revenue to be the range of $240 million and $242 million, a net loss in the range of $15.3 to $16.3 million, or $(0.26) to $(0.28) per share and for Adjusted EBITDA to be in the range of $8.0 million to $9.0 million compared with its previous guidance for fiscal 2012 revenue to be between $240 million and $245 million, a net loss in the range of $14.0 to $18.0 million or ($0.25) to ($0.32) per share and for Adjusted EBITDA to be in the range of $8.0 million to $12.0 million. For the fourth quarter of 2012, the Company expects revenues to be between $63.0 million and $65.0 million, a net loss in the range of $2.5 million to $3.5 million, or $(0.04) to $(0.06) per share, and Adjusted EBITDA in the range of $2.0 million to $3.0 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $57.0 million, net profit of $(2.8), EBITDA of $3.8 million and EPS of $(0.05) for the fourth quarter of 2012; revenues of $241 million for fiscal 2012. Full Article
NxStage Medical, Inc. Issues Q3 2012 Guidance; Reaffirms FY 2012 Guidance
NxStage Medical, Inc. announced that for the third quarter of 2012, it expects revenues to be between $60.0 million and $61.0 million, a net loss in the range of $3.5 million to $4.5 million, or $(0.06) to $(0.08) per share, and adjusted EBITDA in the range of $1.5 million to $2.5 million. The Company reaffirmed its fiscal 2012 guidance, which includes Asahi dialyzer sales. Full Article
NxStage Medical, Inc. Issues Q2 2012 Guidance; Revenue, Net Income And EBITDA Guidance Below Analysts' Estimates; Reaffirms FY 2012 Guidance
NxStage Medical, Inc. announced that for second quarter of 2012, it expects revenues to be between $57 million and $58 million, a net loss in the range of $5.0 million to $6.0 million, including $1.0 million for the write-off of the unamortized debt discount related to the Asahi debt conversion, or $(0.09) to $(0.10) per share (EPS) and adjusted EBITDA in the range of $1.0 million to $2.0 million. The Company reaffirmed fiscal 2012 guidance. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of revenue of $60 million, net income of $(4.7) million, EPS of $(0.09) and EBITDA of $2.44 million for second quarter of 2012; revenue of $242 million, net income of $(15.9) million, EPS of $(0.29) and EBITDA of $(12.8) million for fiscal 2012. Full Article
NxStage Medical, Inc. Extends Agreement to Supply Streamline Bloodlines, MasterGuard and Buttonhole Needle Technology to B. Braun
NxStage Medical, Inc. announced that its Medisystems in-center business and B. Braun Medical Inc. have agreed to extend their supply agreement under which Medisystems will supply B. Braun with its Streamline blood tubing sets for use on the B. Braun Dialog and Dialog+ hemodialysis systems, Medisystems MasterGuard and Buttonhole needles, and ancillary products for sale in the U.S. Under the terms of the amended agreement, which has been extended through 2014, B. Braun will provide sales, marketing and clinical support to its customers in the U.S. Full Article
NxStage Medical, Inc.'s Medisystems Division Secures Multi-Year Contract To Supply Atlantic Dialysis Management Services
NxStage Medical, Inc. announced that its Medisystems division has won a multi-year contract to supply the Vasc-Alert Access Surveillance Solution to Atlantic Dialysis Management Services centers. Full Article
NxStage Medical, Inc. Issues Q4 2011 Guidance; EBITDA Guidance Below Analysts' Estimates; Raises FY 2011 Revenue Guidance; Reaffirms FY 2011 Earnings Guidance
NxStage Medical, Inc. announced that for the fourth quarter of 2011, the Company is forecasting revenue to be within a range of $55.5-$56.5 million. At this revenue level, the Company would expect a net loss in the range of $4.5-$5.5 million or ($0.08)-($0.10) per share (EPS), and adjusted EBITDA in the range of $1.5-$2.5 million for the fourth quarter of 2011. The Company's fourth quarter revenue guidance translates to an upward revision of the Company's annual guidance, putting expected revenue above the top end of its previous range. The Company now expects annual revenue to be within a range of $216-$217 million compared with previous guidance for revenue to be within a range of $210-$215 million. The Company continues to expect a net loss in the range of $19-$23 million or ($0.36)-($0.43) per share, and for adjusted EBITDA to be in the range of $6.0-$10.0 million for fiscal 2011. According to I/B/E/S Estimates, analysts are expecting the Company to report revenues of $56.2 million, net profit of $(4.6), EBITDA of $2.9 million and EPS of $(0.09) for the fourth quarter of 2011; revenues of $214 million, net loss of $(22) million, EPS of $(0.40) and EBITDA of $8.1 million for fiscal 2011. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
